RESEARCH

Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 14, 2023

We anticipate reaching important milestones in the upcoming quarters,” said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • We anticipate reaching important milestones in the upcoming quarters,” said Anthony Fernando, Asensus Surgical President and CEO.
  • The LUNA System's development is in progress and is now entering the testing and evaluation phase before regulatory submissions.
  • Future milestones include freezing the system's design in early 2024, followed by verification and validation testing, and pilot manufacturing.
  • Revenue in the third quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.3 million in services.

Asensus Surgical Announces Sale of Senhance Robotic System

Retrieved on: 
Tuesday, November 14, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and the patient, announced that a Senhance® Surgical System was sold to the Company’s distribution partner, and will be placed in a pediatric hospital in the Commonwealth of Independent States (CIS) region.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and the patient, announced that a Senhance® Surgical System was sold to the Company’s distribution partner, and will be placed in a pediatric hospital in the Commonwealth of Independent States (CIS) region.
  • “We're pleased to see the increasing adoption of Senhance by pediatric-focused hospitals.
  • Senhance’s specialized technology such as 3mm instrumentation, 5mm camera scope, and advanced clinical intelligence, offers the potential to reduce invasiveness and enhance precision, particularly in pediatric patients," noted Anthony Fernando, President and CEO of Asensus Surgical.
  • “We look forward to extending these capabilities to more pediatric hospitals and patients globally, ultimately contributing to an improved standard of patient care.”
    Caption: A Senhance Surgical System will be placed in a pediatric hospital in the Commonwealth of Independent States (CIS) region.

Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System

Retrieved on: 
Monday, November 13, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced an agreement with diversified manufacturer Flex (NASDAQ: FLEX) for design and advanced manufacturing services for Asensus’s previously-announced LUNA Surgical System , a next-generation surgical robot platform.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced an agreement with diversified manufacturer Flex (NASDAQ: FLEX) for design and advanced manufacturing services for Asensus’s previously-announced LUNA Surgical System , a next-generation surgical robot platform.
  • Flex will provide a range of services across LUNA’s product lifecycle to enable Asensus Surgical to deliver the platform at scale, faster.
  • These include design for manufacturing services to assess and improve LUNA’s manufacturability, ensuring a seamless and fast transition from product design to ramp to full-scale manufacturing.
  • “Our collaboration with Asensus Surgical will enable them to deliver the LUNA platform to market faster, reliably, and sustainably, making next-generation surgical robotics solutions more accessible to patients worldwide.”

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 10, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc.
  • Amended and Restated 2022 Employment Inducement Incentive Award Plan (the “Plan”).
  • The Plan was approved by Science 37’s Board of Directors in November 2023.
  • In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

Retrieved on: 
Friday, November 10, 2023

These real-world observations suggest ORLADEYO can have a meaningful impact on the lives of people who have HAE with normal C1-INH.

Key Points: 
  • These real-world observations suggest ORLADEYO can have a meaningful impact on the lives of people who have HAE with normal C1-INH.
  • The company also announced a new post-hoc analysis from the APeX-S clinical trial that showed a sustained reduction in HAE attacks compared to patients’ self-reported baseline attack rates.
  • “The ability to compare patients’ treatment outcomes with their HAE attack rates at baseline is tremendously helpful to characterize the impact of a prophylactic therapy.
  • Patients who were treated with ORLADEYO experienced a sustained reduction in HAE attacks compared to their self-reported baseline attack rates, suggesting a reduction in disease burden and durable treatment effect.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • Event: Jefferies London Healthcare Conference in London, UK
    Time: Company Presentation at 5:00 a.m.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.

Switzerland Data Center Market Investment Analysis Report 2023-2028: Opportunities in IT, Electrical, Mechanical Infrastructure, General Construction, and Tier Standards - ResearchAndMarkets.com

Retrieved on: 
Friday, December 8, 2023

The "Switzerland Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Switzerland Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • Some key investors in the Switzerland data center market include Digital Realty, Equinix, NTT Global Data Centers, STACK infrastructure, Vantage Data Centers, and Green, among others.
  • The Switzerland data center market is experiencing robust growth driven by technology penetration, data traffic surge, and proactive government initiatives.
  • A detailed study of the existing Switzerland data center market landscape, an in-depth industry analysis, and insightful predictions about market size during the forecast period.

Bahrain Data Center Market Investment Analysis Report 2023-2028: Opportunities for Existing and Upcoming Facilities in IT, Electrical, Mechanical Infrastructure, Construction, and Tier Standards - ResearchAndMarkets.com

Retrieved on: 
Monday, November 20, 2023

The "Bahrain Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bahrain Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Bahrain data center market is expected to reach a value of 305.9 million by 2028 from $166.4 million in 2022, growing at a CAGR of 10.68% from 2022-2028
    This report analyses the Bahrain data center market share.
  • In the Bahrain data center market, Manama is a significant location for data center development; Hamala is also emerging as a new location for development.
  • The Bahrain data center market is witnessing investments from new entrants, which includes the Middle Eastern major colocation operator Gulf Data Hub.

Ethiopia Data Center Market Investment Analysis & Growth Opportunities Report 2023-2028 Featuring Key DC Investors - Raxio Data Centres, Safaricom, and wingu.africa - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023

The "Ethiopia Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ethiopia Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • Data center development in Ethiopia has gained momentum with investments from notable operators like Raxio Data Centres and Safaricom, marking a steady growth trajectory for the country's data center infrastructure.
  • The Ethiopia data center market is set to become more competitive, attracting new investors starting from 2022.
  • A detailed study of the existing Ethiopia data center market landscape, an in-depth industry analysis, and insightful predictions about market size during the forecast period.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.